The expansion puts an end to a decade-plus political battle in North Carolina over Medicaid and illustrates mounting support for the program.
North Carolina becomes 40th state to expand Medicaid Read More »
Despite a tough financing market, ArriVent Biopharma closed a $155 million Series B to fund a pivotal Phase III trial of its non-small cell lung cancer asset.
ArriVent Snags $155M for NSCLC Treatment in Record Low Series B Period Read More »
UNITY Biotechnology’s lead asset, UBX1325, failed to show non-inferiority to Regeneron’s blockbuster Eylea in a Phase II wet age-related macular degeneration trial.
UNITY Shares Nearly Halved after Lead Asset Fails to Match Regeneron’s Eylea Read More »
If management isn’t your strength, there are several upper-level positions that don’t require you to manage others. Here are five high-paying life science jobs that don’t include management.
5 High-Paying Life Science Jobs that Don’t Include Management Read More »
The agency is providing a 180-day transition period for devices that were exempted during the pandemic, and said companies that currently have an EUA should start preparing.
FDA details plan to end emergency use authorizations Read More »
The bipartisan legislation, if enacted, would speed the coverage determination process for FDA-approved devices.
Bill would require Medicare to cover breakthrough devices for four years Read More »
Employment in ambulatory services is now well above pre-pandemic levels, as healthcare jobs recuperate from pandemic-driven shortages, according to nonprofit Altarum.
Pandemic-driven healthcare staffing shortages have mostly eased, report finds Read More »
CVS expects its $8 billion buy of home healthcare provider Signify to close on or near Wednesday, subject to certain conditions.
Las proteínas no canónicas podrían ser una nueva fuente de dianas terapéuticas para desarrollar tratamientos de inmunoterapia contra el cáncer. Unos investigadores han constatado que algunas proteínas no canónicas pueden ser presentadas en la …
Nueva vía para desarrollar tratamientos de inmunoterapia contra el cáncer Read More »
Topline data from the Phase III NATALEE study showed Novartis’ Kisqali met its primary endpoint, reducing the risk of recurrence in early breast cancer.
Novartis’ Kisqali Cuts Recurrence Risk in Early-Stage Breast Cancer Read More »
